Summary. The insulin-like growth factor I receptor and the activity of its associated tyrosine kinase activity were characterised in wheat germ agglutinin extracts from skeletal muscle biopsies from nine control and ten obese Type 2 (non-insulindependent) diabetic subjects, who had marked peripheral in vivo insulin resistance for glucose disposal and hyperinsulinaemia. In parallel studies, the concentration of the insulin receptor and its tyrosine kinase activity were examined in the biopsy extracts and compared to the findings for the insulinlike growth factor I receptor system. Specific binding sites for insulin-like growth factor I were detected. The receptor binding of insulin-like growth factor I was not changed in the obese diabetic subjects as compared to binding activity in the biopsies from the control subjects. The molecular weight of the insulin-like growth factor I receptor alpha subunit was similar in both groups (135 kDa). The insulin-like growth factor I stimulated tyrosine kinase activity was also similar for the two groups. In contrast, insulin binding activity was 30% less in the receptor extracts from the in vivo insulin resistant group when compared to the control group. Moreover, insulinstimulated tyrosine kinase activity was reduced in the former group by 40% when the value was corrected for insulin binding. Thus, specific insulin-like growth factor I receptors are present in human skeletal muscle. These receptors are normal in insulin resistant obese Type 2 diabetic subjects. The findings argue that alterations in the insulin receptor number and tyrosine kinase activity of muscle, which may underlie the marked insulin resistance found in obese Type 2 diabetic patients for glucose disposal, are quite specific for the insulin receptor, since the closely related insulin-like growth factor I receptor was not affected in these patients.
Insulin-like growth factor I (IGF-I) action is associated with growth promotion and the production of insulinlike effects in a number of tissues [1, 2] . The receptor for IGF-I mediates part or all of these effects, depending on the tissue and the extent of cross-reaction of the hormone with the insulin receptor. This cross reaction arises from the similarity between IGF-I and proinsulin and from the highly homologous structural identity that exists between the two receptor systems [1] [2] [3] . For example, selected areas in the deduced amino acid sequences for the two receptors for the putative hormone binding regions and for the tyrosine kinase catalytic sites range from 48% to 84% identity [3] . Because of this high homology, regulatory processes that control receptor number or that modulate tyrosine kinase activity may act on both receptors. This concept is supported by studies of muscle from obese mice that demonstrate resistance to both IGF-I and insulin as measured by the activation of glucose transport and the stimulation of glycogen synthase [4] . Other studies conducted in tissue culture have also demonstrated examples of parallel regulation of both receptor systems [5] , as well as instances in which the two systems are not regulated in tandem [6] . The IGF-I receptor in human muscle has not been studied so far. Such studies are of importance for the understanding of normal physiology, as well as of insulin resistance and glucose intolerance, since skeletal muscle plays a major role in glucose disposal.
Recent work from our laboratory [7] and from the laboratories of others [8] [9] [10] [11] have shown an alteration in the tyrosine kinase activity of the insulin receptor in the insulin target tissues from patients with most common forms of insulin resistance, i.e. obesity with or without Type 2 (non-insulin dependent) diabetes mellitus. In skeletal muscle from these subjects, the degree of the reduction in insulin-stimulated kinase activity corrected for insulin binding can reach 40% [7, 9] . Therefore, since skeletal muscle also contains the IGF-I receptor [4] , an alteration in the tyrosine kinase activity of this receptor would be expected in common insulin resistant states if parallel regulation with the insulin receptor occurs. This possibility was examined by the present study in which IGF-I binding activity, and IGF-I stimulated tyrosine kinase activity were measured in receptor extracts from skeletal muscle biopsies of control subjects and obese Type 2 diabetic subjects (where marked insulin resistance was expected). Furthermore, it is not known if the IGF-I receptor is present in any of the human target tissues for insulin. So far, only the liver and the adipose tissue has been investigated in this respect; no IGF-I receptors were found in adult human fat and liver cells [12, 13] . Parallel studies of the insulin receptor in the same muscle extracts were conducted as well, and the results compared to the findings from the IGF-I investigations.
Subjects and methods
N. Livingston et al.: IGF-I receptor in muscle initial priming dose for the first 10 min and then as a continuous infusion for 110 min at a rate of 56 mU/m2/min in all subjects. This rate of infusion resulted in a mean plasma insulin concentration of 113 mU/l (range of 71-145 mU/l). Plasma glucose concentration was measured every 5 min with a glucose analyzer Ii (Beckman Instruments, Fullerton, Calif, USA). The target plasma glucose concentration during the clamp procedure was 5.3 mmol/1, which was reached within 60 min of the start of insulin infusion. In two control and two diabetic subjects, endogenous glucose production was measured during the glucose clamp procedure using D-3-(3H) glucose. Diabetic subjects received a priming dose of 40 ~tCi and normal individuals a dose of 20 ~tCi in a 2131 ml intravenous bolus. Continuous infusions of radiolabelled glucose of 0.4 ~tCi/min and 0.2 ~tCi/min were carried out for 180 min and 120 min respectively, for the diabetic and control subjects before the start of the insulin infusions. Plasma samples were taken every 5 min during the last 30 min of this period to determine the specific radioactivity of the glucose pool as previously described [181.
Steady-state plasma glucose and insulin concentrations were determined and the M value (rate of glucose infusion) was calculated [19] . The rate of endogenous glucose production was calculated as described previously [19] .
Materials
Human recombinant IGF-I was supplied by Kabi-Vitrum Co., (Stockholm, Sweden) and porcine insulin by Eli Lilly Co., (Indianapolis, Ind, USA). Mono-iodinated (A-14) 125I-insulin, 125I-IGF-I, and D-3(3H)-glucose were purchased from Amersham (London, UK). The monoclonal antibody, alpha-IR3, was kindly supplied by Dr. S. Jacobs (Burroughs Wellcome, Research Triangle Park, NC, USA). Semisynthetic regular human insulin for the euglycaemic insulin infusion studies was provided by Novo (Copenhagen, Denmark). The sources of the other reagents have been reported previously [8, 14] .
Human subjects
All of the subjects were 60-year-old men who participated in a health screening study in Uppsala, a middle-sized Swedish town [15] . The subjects were healthy and drug-free except for the presence of obese Type 2 diabetes in 10 of the 19 individuals. This condition, which was diagnosed during the health screening procedures, was not treated prior to the investigation. According to dietary histories [15] , all subjects consumed a similar diet that consisted of 15% protein, 50% carbohydrate, and 35% fat with an intake of 10.5 megajoule/24 h.
Following an overnight fast, plasma levels for glucose and insulin were determined as previously described [15] . Serum levels for total IGF-I were kindly measured by the Clinical Research Center, Rochester, NY, USA, using a radioimmunoassay kit (Incstar Corporation, Stillwater, Minn, USA). The measures were performed exactly as described by the manufacturer. Also, an intravenous glucose tolerance test was conducted and body mass index measured [15] . On separate days after an overnight fast, either an euglycaemic insulin clamp was performed (see below) or three biopsies (100 mg 250 g total weight) were taken from the left vastus lateralis muscle and immediately frozen in liquid N2.
The study was approved by the Ethics Committee of Uppsala University. The experimental procedures were explained in detail to each participant and informed consent was obtained.
Glucose clamp technique
The in vivo response of the subjects to insulin was measured by the euglycaemic clamp technique as described in detail by DeFronzo et al. [16] . Arterialised venous blood (PA 02>85 mmHg) was used for measurements of plasma glucose levels [17] . Insulin was infused as an
Extraction of receptors for insulin and IGF-I
The muscle biopsies were stored in liquid N2 and all subsequent steps in receptor isolation were carried out at 4~ The receptors were extracted as described [7' ]. The extract was placed on a column of wheat germ agglutinin (WGH) coupled to agarose [14] . The extract was cycled over the column and washed as described [8] . Following centrifugation of the columns to remove the wash buffer from the column bed [8] , a 0.3 mol/1 n-acetylglucosamine solution that contained 50 mmol/1 HEPES, pH 7.4 and 0.1% Triton X-100 was added to the capped column and mixed with the WGA-agarose. After an incubation period of 1 h at 4~ the column was uncapped and the eluate collected by centrifugation. The eluate was divided into equal samples that were used for hormone binding studies and studies of the tyrosine kinase activities of the insulin and IGF-I receptors. Protein content of the samples was determined by the Bio-Rad method. It varied between 12.5 to 32.5 ng ]per ~tl of WGA extract. Recoveries of the receptors for IGF-I and insulin as measured by hormone binding assays were, respectively, 76% and 95%.
Hormone binding studies
The specific binding of 125I (A-14) insulin and 125I-IGF-I was determined in duplicate by a microassay method described previously [7] . In brief, WGA extract was incubated in the presence or absence of native hormone and 50 pmol/1 of the radiolabelled ligand. Non-specific binding of 125I-IGF-I as determined with 1 l.tmol/1 unlabelled IGF-I was approximately 20% of total tracer binding compared to non-specific binding of 10% for 125I-insulin. Degradation of radiolabelled IGF-I or insulin was less than 5% of the tracer added to the assay. Hormone binding activity was linearly related to the amount of WGA extract added to the assay. The intraassay coefficient of variance for insulin and IGF-I binding of tracer hormone was 9%.
Tyrosine kinase assay
The tyrosine kinase assay is a modification of a previous assay [7] . The assay was modified by the step that allowed the receptors to undergo autophosphorylation before the exogenous substrate was added. This step prevents the substrate from inhibiting receptor autophosphorylation that would in turn inhibit the full activation of the kinase activity [20] . The assay was conducted following a 3 h incubation at 4~ of the p-nitrophenylphosphate was added and the incubation continued for 5 min at 24 ~ C to allow autophosphorylation of the receptor before the addition of the substrate and radiolabelled ATP. A 10 ~1 amount of the artifical substrate, GlusoTyr20, (5 mg/ml) mixed with 5 l-tCi of (gamma-32P) ATP was added to start the substrate reaction. The assay, which was run in duplicate, was terminated after 20 rain at 24 ~ C and the amount of phosphate incorporated into GlusoTyr20 was measured as previously described [7] . IGF-I and insulin-stimulated phosphorylation of GlusoTyr20 was linear with respect to time and to the amount of hormone receptors added. The hormone stimulated activity was dependent on the presence of the GlusoTyr20; in its absence, IGF-I stimulation of protein phosphorylation was completely absent, and insulin stimulation was only 11% of the amount found in the presence of the artifical substrate. The intraassay coefficient of variation for the tyrosine kinase activity measurements was 5%. Since the relationship between receptor content and total protein concent in the WGA extract was unknown, all tyrosine kinase data were normalised for binding activity at tracer concentration for IGF-I or insulin.
Cross-linking studies of the IGF-I receptor
Pooled muscle biopsies from three normal subjects and three obesediabetic subjects were extracted and partially purified on WGA-agarose as described above. The column eluate from each group was divided into three equal parts. 125I-IGF-I (0.5 nmol/1) was added to each fraction in the presence or absence of 1 gmol/l native IGF-I or 100 ~tmol/1 insulin. After an overnight incubation at 4~ the hormone receptor complex was precipitated by the polyethylene glycol method. The pellet was washed once with 10% polyethylene glycol and resuspended in 300 ~1 of a 50 mmol/1 HEPES buffer, pH 7.4, that contained 0.05% Triton X-100. Disuccidimidyl suberate (0.5 mmol/1) was added to the suspended complex; after 1 h at 4~ the reaction was terminated by the addition of 20 mmol/1 Tris-HCI, pH 7.4 [14] . The reaction mixture was precipitated by the polyethylene glycol method and subjected to PAGE-SDS (7.5% acrylamide) and autoradiography as previously described [14] .
Statistical analysis
The statistical significance of the results was analysed by Student's unpaired t-test. The values are the mean + SEM. The coefficient of variance for the different assays was calculated from the results of duplicated determinations in the whole material (29 subjects). Table 1 summarises the characteristics of the control individuals and the obese Type 2 diabetic subjects. The obese Type 2 diabetic group had clearly elevated fasting glucose and insulin levels, as well as, abnormal intravenous glucose tolerance. This indicates overall insulin resistance. The levels of IGF-I were almost doubled in the diabetic group (p< 0.025). Table 2 shows the results of the glucose clamp studies carried out with the control and diabetic subjects. Insulin resistance was demonstrated in the diabetic subjects by a greater than 50% decrease in the M value which occurred even though the steady-state insulin levels were higher than the levels present in the control group.
Results

Patient characteristics
It was observed that 90% or greater suppression of basal endogenous glucose production was achieved by the infusion of insulin in two control and two diabetic subjects. Thus, the decrease in the M values for the obese diabetic patients was not the result of a failure of suppression of hepatic glucose production. Instead, it reflects the degree of insulin resistance in peripheral tissues.
Biochemical studies
High affinity specific IGF-I binding was detected in the extracts as illustrated by a 50% inhibition of tracer hormone binding by 0.3 nmol/1 native IGF-I, whereas native insulin was much less effective (Fig.l) . Insulin binding demonstrated the properties expected of the insulin receptor. Also, the monoclonal antibody against the IGF-I receptor, alpha-IR3 [21] , reduced IGF-I binding to 46 _+ 5% of control (100%) in comparison to insulin binding, which was not altered by the antibody. Affinity labelling studies with t25I-IGF-I show that the material specifically labelled had a molecular weight of 135 kDa (Fig. 2) . This was appropriate for the IGF-I receptor alpha subunit [22] . There was also labelling of very large molecular weight material near the top of the gel that was not resolved by gel electrophoresis. It . Essentially the same results were found with muscle extracts from obese diabetic subjects (data not shown). The ability of 100 ~tmol/1 insulin to discriminate the IGF-I receptor from the IGF-II receptor was used throughout the 125I-IGF-I binding studies. The difference between the amounts of 125I-IGF-I displaced by 1 ~mol/1 IGF-I and 100 gmol/1 insulin amounted to 13-15%, i. e. 100 ~mol/1 insulin was about 85% as effective as 1 ~tmol/1 IGF-I in inhibiting tracer IGF-I binding. As shown in Figure 3 , this difference was the same for control and diabetic subjects. Therefore, the IGF-I binding activity was contributed to primarily by the type I IGF receptor, and the small amount of IGF-I binding to the type II receptor or serum binding proteins, which may be present in the samples did not differ from normal in the obese diabetic group. Figures 3 and 4 illustrate the lack of change in the specific binding if IGF-I to the IGF-I receptor in the obese diabetic subjects. The displacement curve with native IGF-I was basically the same for the two groups. In addition, the B / F values for tracer 125I-IGF-I were not different for the two groups. This observation is in contrast to the findings with the insulin receptor. As shown in Figure 3 , trace insulin binding by the obese diabetic group was significantly lower by 30% when compared to the binding activity of the control group.
The tyrosine kinase activity of the IGF-I receptor and the insulin receptor were measured and compared between the two groups (Fig. 5) . Basal phosphate incorporation (absence of hormone) was not different per ~tg of protein between the two groups, i.e. 2.4_+ 0.2 pmol phosphate incorporated per gg protein per 20 rain for the control group versus 2.3 _+ 0.3 for the obese diabetic group. More importantly, there was no difference between the two groups for IGF-I stimulation of tyrosine kinase activity in the WGA extracts. IGF-I generated similar amounts of phosphorylated substrate by receptor preparations from both groups when expressed per IGF-I binding activity as shown or per p~g of protein in the WGA extract. It should be noted that the kinase activity stimulated by IGF-I resulted in the phosphorylation of tyrosines since no stimulation was observed in the absence of the substrate, GlusoTyr20. A comparision of the kinase activities for the two receptor systems showed that the insulin receptor was much more active than the IGF-I receptor. Although the muscle extracts from the obese diabetic group had a normal response to IGF-I, they lacked a normal response to insulin (Fig. 5) . These studies, which were carried out in the same preparations and in parallel with the IGF-I studies, clearly showed a decrease in the kinase activity of the insulin receptor for both concentrations of insulin used. Because of this decrease in insulin receptor kinase activity, the IGF-I -insulin ratio for kinase stimulation -was altered in the Type 2 diabetic obese subjects. Thus, there was proportionally more IGF-I stimulation of tyrosine kinase activity in the diabetic preparations than in the control group.
Discussion
The similarities between the receptors for IGF-I and insulin [1] [2] [3] and their coupled regulation under certain conditions [4] prompted us to examine the IGF-I receptor in skeletal muscle from normal subjects and obese Type 2 diabetic subjects who are insulin resistant and have alterations in the insulin receptor in target tissues [7] [8] [9] [10] [11] . To the best of our knowledge, the human muscle IGF-I receptor has not been characterised previously. The initial studies characterised the IGF-I binding activity of the muscle extracts to validate that the IGF-I receptor was being studied and not the IGF-II receptor or IGF-I serum binding proteins.
The results from the affinity cross-linking experiments with 125I-IGF-I and the 125I-IGF-I binding studies strongly argues that the IGF-I receptor contributes to the binding activity in the extracts from the muscle biopsies. This is in contrast to human fat and liver cells -the other two major insulin target cells which do not seem to contain IGF-I receptors [12, 13] . However, the data do not completely exclude some contribution by the IGF-II receptor or the serum binding proteins to the binding of IGF-I. The 10-15% of v=l; _L =l tracer IGF-I binding that was not inhibited by 100 gmol/1 insulin may be a result of the binding by these other structures.
As reported, there was no difference in IGF-I binding between obese Type 2 diabetic and control subjects, although obese Type 2 diabetic patients had marked peripheral insulin resistance as evidenced by the glucose clamp studies. This similarity in binding extended to the competition curves for the receptor extracts from both study groups. Therefore, since the IGF-I competition curves and the amount of tracer IGF-I binding were similar for the two groups, the presence of obesity and Type 2 diabetes did not change the hormone binding characteristics and the concentration of the skeletal muscle IGF-I receptor. Increased total serum levels of IGF-I were recorded in the diabetic patients. Usually high hormone levels are associated with receptor down regulation. However, the somatomedins (unlike other peptide hormones) circulate bound to carrier proteins [2] . This fraction, which constitutes most of the circulating IGF-I, may not interact with the receptor. In a previous study on [23] longterm treated Type 2 diabetic patients, decreased serum levels of IGF-I were observed. The difference in results may be due to the fact that we investigated newly diagnosed and untreated patients.
The same tissue extract used to study the IGF-I receptor was also used in the measurement of insulin binding activity. These studies showed a significant decrease of 30% in tracer insulin binding by the extracts from the diabetic patients. This difference was not detected in a previous study of insulin binding in Type 2 diabetes [7] , probably because the degree of fasting hyperinsulinaemia in the previously examined subjects was much less than that found in the present study, i. e. 3-fold the mean control value in the previous study versus 6-fold the control value in the present work. Since down-regulation of the insulin receptor has been closely associated with hyperinsulinaemia, the loss of insulin binding activity should be magnified in the present group of diabetic subjects.
The studies of the tyrosine kinase activity provided information on a second feature of the IGF-I receptor, i.e. its ability to phosphorylate proteins on tyrosine residues [1, 22] . In the presence of 10 nmol/1 IGF-I, this activity, however, was much less (e.g. about 15%) than the comparable activity found with 10 nmol/1 insulin stimulation of the insulin receptor. With this hormone concentration, there is little cross-binding of ligands by the two types of receptors [1] . Thus, the difference in the kinase activity between the two receptors may stem from differences in substrate preference or in the conditions of the assay. Alternatively, the tyrosine kinase activity of the IGF-I receptor is less active than the kinase actvity of the insulin receptor.
The IGF-I stimulated kinase activity was essentially the same in the receptor extracts from obese diabetic and control muscles. In this respect, it should be noted that normal tyrosine kinase activity of the IGF-I receptor in erythrocytes has been demonstrated in Type 2 diabetes [24] .
The results with the IGF-I receptor kinase activity in Type 2 diabetes are clearly different from the findings with the kinase activity of the insulin receptor. Thus, in the same receptor preparations used in the IGF-I studies and analysed at the same time, we found a marked reduction in the insulin stimulated tyrosine ki-N. Livingston et al.: IGF-1 receptor in muscle nase in muscle extracts from the diabetic subjects. The results of the kinase studies of the insulin receptor in obese Type 2 diabetic patients also agree with previous findings by us [7] and others [8] [9] [10] [11] 24 ] that document comparable reductions in its activity. Also, the results further support the conclusion drawn from the hormone binding studies, that the alterations found in the obese Type 2 diabetes syndrome involve only the insulin receptor and not the receptor for IGF-I. The different results obtained with receptor kinase activity for IGF-I and insulin in the latter condition cannot be explained by receptor cross reactions. If so, both tyrosine kinases should be affected by the obese diabetes state.
In summary, the present studies show that a biologically active IGF-I receptor is present in human skeletal muscle. This receptor is not affected by the processes that induces alterations in the insulin receptor of muscle in insulin resistant obese Type2 diabetic patients. Whether the latter is true for non-obese Type 2 diabetic patients or non-diabetic obese subjects remains to be established. However, it is possible to consider that the two receptor systems are regulated by separate processes, at least in human muscle.
